A bifunctional compound of Formula X: wherein: the Targeting Ligand is of Formula TL-I: or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein: A is O, NR 5, or NR 5 C; B is S t, O, or NR 6; X is N or CH; R 1 is H, (C 1 -C 4) alkyl, or (C 1 -C 4) haloalkyl; R 2 is H, (C 1 -C 4) alkyl, or (C 1 -C 4) haloalkyl; R 3 is H, (C 1 -C 4) alkyl, (C 1 -C 4) haloalkyl, (C 1 -C 4) alkoxy, or (C 1 -C 4) haloalkoxy; R 4 is (C 1 -C 4) alkyl, (C 1 -C 4) haloalkyl, (C 1 -C 4) alkoxy, or (C 1 -C 4) haloalkoxy; R 5 is H or (C 1 -C 3) alkyl; R 6 is H or (C 1 -C 3) alkyl; and t is 0, 1, or 2, or 3, wherein the Targeting Ligand is bonded to the Linker via the next to the Linker is of Formula L0: or an enantiomer, diastereomer, or stereoisomer thereof, wherein: p1 is an integer selected from 0 to 12; p2 is an integer selected from 0 to 12; p3 is an integer selected from 1 to 6; each W is independently absent, CH 2, O, S, NH, or NR 19; Z 1 is absent, CH 2 C NH, CH 2, O, NH, NR 19, or each R 19 is independently C 1 -C 3 alkyl; R 20 is absent, CH=CH, CH=CH(CH 2) 1-3, or (CH 2) 1-3 CH=CH, wherein R 20 is bonded to the remainder of the Linker; Q is absent or NHC CH 2, wherein the Linker is covalently bonded to a Degron via the next to Q, and covalently bonded to a Targeting Ligand via the next to Z 1; and the Degron is of Formula D1 or D2: or an enantiomer, diastereomer, or stereoisomer thereof, wherein: Y is a bond, (CH 2) 1-6, (CH 2) 0-6 -O, (CH 2) 0-6 -C NR 11, (CH 2) 0-6 -NR 11 C, (CH 2) 0-6 -NH, or (CH 2) 0-6 -NR 12; Z is C or C(R 13) 2; R 11 is H or C 1 -C 6 alkyl; R 12 is C 1 -C 6 alkyl or C -C 1 -C 6 alkyl; each R 13 is independently H or C 1 -C 3 alkyl; each R 14 is independently C 1 -C 3 alkyl; R 15 is H, deuterium, C 1 -C 3 alkyl, F, or Cl; each R 16 is independently halogen, OH, C 1 -C 6 alkyl, or C 1 -C 6 alkoxy; q is 0, 1, or 2; and v is 0, 1, 2, or 3, or or an enantiomer, diastereomer, or stereoisomer thereof, wherein: each R 17 is independently C 1 -C 3 alkyl; q' is 0, 1, 2, 3 or 4; and R 18 is H or C 1 -C 3 alkyl, wherein the Degron is bonded to the Linker via A is O, NR 5, or NR 5 C; B is S t, O, or NR 6; X is N or CH; R 1 is H, (C 1 -C 4) alkyl, or (C 1 -C 4) haloalkyl; R 2 is H, (C 1 -C 4) alkyl, or (C 1 -C 4) haloalkyl; R 3 is H, (C 1 -C 4) alkyl, (C 1 -C 4) haloalkyl, (C 1 -C 4) alkoxy, or (C 1 -C 4) haloalkoxy; R 4 is (C 1 -C 4) alkyl, (C 1 -C 4) haloalkyl, (C 1 -C 4) alkoxy, or (C 1 -C 4) haloalkoxy; R 5 is H or (C 1 -C 3) alkyl; R 6 is H or (C 1 -C 3) alkyl; and t is 0, 1, or 2, or 3, p1 is an integer selected from 0 to 12; p2 is an integer selected from 0 to 12; p3 is an integer selected from 1 to 6; each W is independently absent, CH 2, O, S, NH, or NR 19; Z 1 is absent, CH 2 C NH, CH 2, O, NH, NR 19, or each R 19 is independently C 1 -C 3 alkyl; R 20 is absent, CH=CH, CH=CH(CH 2) 1-3, or (CH 2) 1-3 CH=CH, wherein R 20 is bonded to the remainder of the Linker; Q is absent or NHC CH 2, Y is a bond, (CH 2) 1-6, (CH 2) 0-6 -O, (CH 2) 0-6 -C NR 11, (CH 2) 0-6 -NR 11 C, (CH 2) 0-6 -NH, or (CH 2) 0-6 -NR 12; Z is C or C(R 13) 2; R 11 is H or C 1 -C 6 alkyl; R 12 is C 1 -C 6 alkyl or C -C 1 -C 6 alkyl; each R 13 is independently H or C 1 -C 3 alkyl; each R 14 is independently C 1 -C 3 alkyl; R 15 is H, deuterium, C 1 -C 3 alkyl, F, or Cl; each R 16 is independently halogen, OH, C 1 -C 6 alkyl, or C 1 -C 6 alkoxy; q is 0, 1, or 2; and v is 0, 1, 2, or 3, or each R 17 is independently C 1 -C 3 alkyl; q' is 0, 1, 2, 3 or 4; and R 18 is H or C 1 -C 3 alkyl,